Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
VIENNA, Austria, Jan. 05, 2018 -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.
APEIRON Biologics AG will present at the Biotech Showcase™ as follows:
Date: Tuesday, January 9, 2018
Time: 1:45 p.m. (PST)
Room: Franciscan D, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
In San Francisco, management will conduct a large number of meetings with healthcare investors. If you would like to schedule a meeting, please feel free to reach out to one of the contacts listed at the end of this press release.
About APEIRON Biologics AG
Apeiron is a private biotech company based in Vienna, Austria, engaged in innovative projects in immuno-oncology. Recently, the most advanced program, an antibody-based immunotherapy to treat neuroblastoma, was granted marketing approval in the EU. The company is developing additional immunotherapies, predominantly in clinical stage, based either on targeted, tumor-specific approaches or on the stimulation of the immune system via novel and proprietary modes of action (unique checkpoint blockade mechanisms) to fight cancer by engaging the human body’s natural defense mechanisms. For additional information please go to www.apeiron-biologics.com and follow us on Twitter @apeironbio.
For further information please contact:
APEIRON Biologics AG
Peter Llewellyn-Davies, CFO/CBO
Email: [email protected]
www.apeiron-biologics.com
Investor Relations
LifeSci Advisors, LLC
Chris Maggos
T +1 (646) 597 6989
Email: [email protected]
Media Relations international
MC Services AG
Dr. Claudia Gutjahr-Loeser
T +49 89 210 228 0
Email: [email protected]
Media Relations Austria:
PR&D - Public Relations for Research & Education
T +43 1 505 70 44
Email: [email protected]
